|  |  |
| --- | --- |
| **DATE** | 11/08/2019 |

**Part A. Personal Information**

|  |  |  |
| --- | --- | --- |
| Surname(s) | Lucio-Cazaña | |
| Forename | Francisco Javier De | |
| Social Security, Passport, ID number | 01911884-D | |
| Sex | male | |
| Age | 60 | |
| Researcher codes | WoS Researcher ID *(\*)* | B-8149-2009 |
| SCOPUS Author ID*(\*)* | 6602964830 |
| Open Researcher and Contributor ID (ORCID) | https://orcid.org/0000-0001-9249-8501 |

*(\*) At least one of these is mandatory*

**A.1. Current position**

|  |  |  |
| --- | --- | --- |
| Post/  Professional Category | Professor | |
| UNESCO Code | 3209.90 | |
| Key Words | Inflammation, kidney, Retinoids, hypoxia, Prostaglandins, Extracellular Vesicles | |
| Name of the University/Institution | Universidad de Alcala | |
| Department/Centre | Systems Biology |
| Full Address | Campus Universitario - C/ 19, Av. de Madrid, Km 33,600, 28871 Alcalá de Henares, Madrid. Spain |
| Email Address | javier.lucio@uah.es |
| Phone Number | +34918854515 |
| Start date | 23/02/2011 | |

**A.2. Education** *(title, institution, date)*

|  |  |  |  |
| --- | --- | --- | --- |
| *Year* | *University* | *Degree* | *Title* |
| 18/12/1981 | *Alcala* | *First degree* | *Pharmacist* |
|  |  | *Masters (if appropriate)* |  |
| *06/02/1987* |  | *PhD* | *PharmD* |

**A.3. Indicators of Quality in Scientific Production** *(See the instructions)*

**Sexenios:** 5 (Last: 2017)

**Thesis (last 10 years):** 3 and 1 in process.

**Total cites:** 760


**Cites/year (last 5 years):** 19

**Items that are cited:** 679

**Cites per element:** 20,56

**Publications in Q1:** 35

**h-index:** 12

****

**Part B. Free Summary of CV** *(Max. of 3.500 characters, including spaces)*

Catedrático de Universidad (area of ​​Physiology) since 2011. His research has been directed to the field of inflammation in aspects such as its relationship with aging, the effects of oxygen free radicals, production of extracellular matrix and fibrosis, pain and renal diseases. Committed to research because it keeps him updated as a teacher and it allows him to train Ph. D. students and to attract Ph.Ds to the University. His scientific career in recent years has focused on research in retinoids, prostaglandin E2 and its receptors, always within the context of inflammation and its treatment. The result of these studies was the confirmation of the role of COX / PGE2 in the mechanism of therapeutic action of retinoic acids in different in vivo and in vitro models of renal injury. This mechanism was not exclusive to the kidney, as could be verified in collaboration with Dr. C. Molina, but could also be objectified in the spinal cord (in this case, associated with the induction by retinoids of hyperalgesia and allodynia). More recently, he has focused on PGE2 itself as a key regulator with unsuspected functions and confirmed its role in the regulation of the expression of transcription factors such as HIF-1α and RARβ, on which determined effects of hypoxia, cisplatin, retinoids and inflammatory cytokines. Not only in renal cells, but also prostate cells. Currently, the medium-term scientific-technical objective of its line of research is to explore the physiological and pathological functions of intracellular PGE2 inthe context of acute kidney injury, renal fibrosis and prostatic proliferative pathology, as well as diagnostic and therapeutic applications of this knowledge. We are talking about a practically unexplored field, in which there are only a dozen previous works on the subject (including ours). We think that it is due to the novelty of the concept that PGE2 regulates functions acting on intracellular receptors that published works have not received as much interest as we believe that sooner or later they will wake up as pioneers in this field.

**Part C. Relevant accomplishments**

**C.1. Publications**

Garcia-Pastor, C., Blazquez-Serra, R., Bosch, R. J., Lucio Cazaña, F. J., & Fernandez-Martinez, A. B. Apoptosis and cell proliferation in proximal tubular cells exposed to apoptotic bodies. Novel pathophysiological implications in cisplatin-induced renal injury. Biochimica et Biophysica Acta. Molecular Basis of Disease.2019 1865(9):2504-2515. IF:5.108 Q1

Bernardo-Bermejo, S., Sanchez-Lopez, E., Castro-Puyana, M., Benito, S., Lucio-Cazana, F. J., & Marina, M. L. An untargeted metabolomic strategy based on liquid chromatography-mass spectrometry to study high glucose-induced changes in HK-2 cells. Journal of Chromatography. A. 2019 Mar 9;1596, 124-133. IF :4.169 Q1

Madrigal-Martínez A, Costanzo V, Fernández-Martínez AB, Lucio Cazaña FJ. PGE2 stimulates cancer-related phenotypes in prostate cancer PC3 cells through cyclooxygenase-2. Journal of Cellular Physiology. 2019; 234(5), 754-7559. IF : 4.080 Q1

Madrigal-Martinez, A., Fernandez-Martinez, A. B., & Lucio Cazaña, F. J. Intracrine prostaglandin E2 pro-tumoral actions in prostate epithelial cells originate from non-canonical pathways. Journal of Cellular Physiology. 2018;*233*(4), 3590–3602. IF :4.080 Q1

García-Carmona L, Moreno-Guzmán M, Martín A, Martínez SB, Fernández-Martínez AB, González MC, Lucio-Cazaña J, Escarpa A. Aligned copper nanowires as a cut-and-paste exclusive electrochemical transducer for free-enzyme highly selective quantification of intracellular hydrogen peroxide in cisplatin-treated cells. Biosensors and Bioelectronics. 2017 Oct 15;96:146-51. IF : 7.78 Q1

Fernández-Martínez AB, Martínez SB, Cazaña FJ. Intracellular prostaglandin E2 mediates cisplatin-induced proximal tubular cell death. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2016 Feb 1;1863(2):293-302.. IF : 4.521 Q1

Fernández-Martínez AB, Lucio-Cazaña J. Intracellular EP2 prostanoid receptor promotes cancer-related phenotypes in PC3 cells. Cellular and molecular life sciences. 2015 Sep 1;72(17):3355-73. IF : 5.788 Q1

Fernández-Martínez AB, Lucio-Cazaña FJ. Transactivation of EGFR by prostaglandin E2 receptors: a nuclear story?. Cellular and molecular life sciences. 2015 Jun 1;72(11):2187-98. IF : 5.788 Q1

Fernández-Martínez AB, Cazaña FJ. Prostaglandin E2 induces retinoic acid receptor-β up-regulation through MSK1. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2014 Sep 1;1843(9):1997-2004. FI :4.521 Q1

Fernandez-Martínez AB, Torija AV, Carracedo J, Ramirez R, de Lucio-Cazana FJ. Microparticles released by vascular endothelial cells increase hypoxia inducible factor expression in human proximal tubular HK-2 cells. The international journal of biochemistry & cell biology. 2014 Aug 1;53:334-42. IF:4.046 Q1

Fernández-Martínez AB, Cazaña FJ. Epidermal growth factor receptor transactivation by intracellular prostaglandin E2-activated prostaglandin E2 receptors. Role in retinoic acid receptor-β up-regulation. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2013 Sep 1;1833(9):2029-38. FI : 4.521 Q1

Fernández-Martínez AB, Jiménez MI, Cazaña FJ. Retinoic acid increases hypoxia-inducible factor-1α through intracrine prostaglandin E 2 signaling in human renal proximal tubular cells HK-2. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids. 2012 Apr 30;1821(4):672-83. IF : 5.547 Q1

Olmos G, Arenas MI, Bienes R, Calzada MJ, Aragonés J, Garcia-Bermejo ML, Landazuri MO, Lucio-Cazaña J. 15-Deoxy-Δ12, 14-prostaglandin-J2 reveals a new pVHL-independent, lysosomal-dependent mechanism of HIF-1α degradation. Cellular and molecular life sciences. 2009 Jul 1;66(13):2167-80. IF :5.788 Q1

**C.2. Research Projects and Grants**

**Title:** Consorcio para el estudio del fracaso renal agudo: fisiopatologia, nuevas terapias, biomarcadores y modelos experimentales**.**

**Financing agency:** Comunidad de Madrid (B2017/BMD3686)

**Participating entity/entities:** University of Alcalá and others.

**From:** 2018  **to:** 2021

**Total amount:** 810.362 euros

**Name principal investigator:** Ricardo J Bosch

**Title:** Prostaglandina E2 como mensajero intracelular profibrótico en la patogénesis de la nefropatía diabética.

**Financing agency:** Ministerio de Economía y Competitividad (SAF2014-53218-R)

**Participating entity/entities:** University of Alcalá.

**From:** 2015 **to:** 2017

**Total amount:** 108.900,00 €

**Name principal investigator:** Francisco Javier de Lucio Cazaña.

**Title:** Utilización de modelos animales y celulares para caracterizar el fracaso renal agudo y multiorgánico

**Financing agency:** Comunidad de Madrid (S2010/BMD-2378)

**Participating entity/entities:** University of Alcalá and others.

**From:** 2012  **to:** 2015

**Total amount:** 793.500 euros

**Name principal investigator:** Ricardo J Bosch

**Title:** Regulación cruzada entre hipoxia/factor inducible por hipoxia-1 (HIF-1) y ácido retinoico todo-trans (ATRA)/receptor  de ácido retinoico (RAR) en células proximales tubulares renales: relevancia en el tratamiento por ATRA de la lesión por isquemia/reperfusión (I/R) renal

**Financing agency:** Ministerio de Ciencia e Innovación (SAF2011-26838)

**Participating entity/entities:** University of Alcalá.

**From:** 2012  **to:** 2014

**Total amount:** 96.800 euros

**Name principal investigator:** Javier Lucio Cazaña

**Title:** Ácidos retinoicos y 15-desoxi--∆12,14-prostaglandina J2 como agentes anti-fibróticos en la nefropatía diabética.

**Financing agency:** Comunidad de Castilla la Mancha (JCCM POII10-0034)

**Participating entity/entities:** University of Alcalá.

**From:** 2010  **to:** 2013

**Total amount:** 150.000 euros

**Name principal investigator:** Javier Lucio Cazaña

**Title:** FP7 Coordinate Action “Functional genomic applications in the context of Traditional Chinese Medicine in the Post-Genomic Era (GP-TCM)”.

**Financing agency:** European Union (FP7-Health-2007-B (2007-2.12-7))

**Participating entity/entities:** University of Alcalá and others.

**From:** 2009  **to:** 2012

**Total amount:** 150.000 euros

**Name principal investigator:** Javier Lucio Cazaña

**Title:** Ácidos retinoicos y 15-desoxi-delta12,14-prostaglandina J2 como agentes anti-fibróticos para el riñón.

**Financing agency:** Ministerio de economía y ciencia (SAF2008-01767)

**Participating entity/entities:** University of Alcalá.

**From:** 2008  **to:** 2011

**Total amount:** 121.000 euros

**Name principal investigator:** Javier Lucio Cazaña

**C.3. Contracts**

**C.4. Patents and other IPR**

**C.5, C.6, C.7… Other**

**Thesis supervised (last 10 years)**

1. Coral García Pastor. Prostaglandina E2 intracelular, factor inducible por hipoxia y vesículas extracelulares como mediadores de la lesión de células proximales tubulares Univ Alcalá Fac Medicina. 2016/2019 *Publications:*

Biochim Biophys Acta - Molecular Basis of Disease In press

2. Antonio Madrigal Martínez: Implicación de la prostaglandina E2 intracelular en patología proliferativa prostática. Univ Alcalá Fac Medicina. 2014/2019 *Publications:*

J. Cell. Physiol. In press. J. Cell. Physiol. 2018;233:3590-602. Int. J. Biochem. Cell Biol. 2015; 1;59:52-61.

3. Joao Guilherme Feliciano Da Costa: Redox modulation by 500 mimics in renal cancer: from etiology to progression. Univ Alcalá Fac Medicina. 2014/2018

*Current position:* Professor in Universidade Lusófona, Lisboa, Portugal.

4. Noelia Tejedor García: La medicina herbal china en el contexto de la salud pública europea. Univ Alcalá. Fac de Medicina. 2008/2012 *Publications:* Gac. Sanit. 2018;32:54-60. Gac. Sanit. 2015;29:221-3. J. Ethnopharmacol. 2012; 10;140:545-9.

Current position: Owner of a pharmacy.

****

**Instructions**

**Important Announcement**

Following the Call for Proposals, **ONLY CVS SUBMITTED IN THIS FORMAT WILL BE TAKEN INTO CONSIDERATION**. **CVs presented in other formats WILL BE DISMISSED with no possibilities for modifications.**

**GENERAL CONSIDERATIONS**

Following the call it is mandatory to use the following format when filling the document: Font Times New Roman / Arial (minimum size 11), single interlineal space, lateral margins of 2.5 cm and top and bottom margins of 1.5 cm.

Max. length of the whole document (Part A, B and C) cannot exceed four pages.

**PART A. PERSONAL INFORMATION**

**Researcher ID** is a unique identifier that consists of alphanumeric characters that enable researchers to manage their publication lists, track their times cited counts and h-index, identify potential collaborators and avoid author misidentification. It is hosted by Web of Science.

Access: Web of Science > My Tools > Researcher ID.

**Author ID** is a unique identifier that consists of alphanumeric characters that enable researchers to manage their publication lists, track their times cited counts and h-index, identify potential collaborators and avoid author misidentification. It is assigned automatically by SCOPUS. You can find an author identifier by running a search for that author. It will appear underneath the author details.

Access: SCOPUS > Author Feedback Wizard> Researcher name.

**Open Researcher and Contributor ID (ORCID)** provides a persistent digital identifier that distinguishes the researcher from every other person and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between you and your professional activities ensuring that your work is recognized.

Access: [www.orcid.org](http://www.orcid.org)

**A.3. Indicators of Quality in Scientific Production**

Please add information on a) total number of citations, average number of citations during the last five years, b) total number of publications in the first quartile (Q1) and first decile (D1), c) h-index, d) thesis supervised, and e) any other indicators that you may consider relevant.

To calculate these values, use default data collected in the Web of Science or Scopus. When this is not possible, other indicators may be used, specifying the reference database.

**PART B. FREE SUMMARY OF CV** *(Max. of 3.500 characters, including spaces)*

Describe briefly your scientific career, the main scientific-technical achievements, and the mid-to-long term scientific-technical interests and objectives of your research agenda. Indicate any other aspects that you may consider important to understand your career path.

**PART C. ACCOMPLISHMENTS (Order by typology)**

Given the limitations in number of characters, please mention the most relevant achievements sorted by the typology that best suits your scientific profile. Please be clear and avoid ambiguities.

Use reverse chronological order within each section. Limit your merits over the past 5 years, except for those which have an extraordinary importance for your CV.

**C.1. Publications**

Include a full review of relevant 5 to 10 publications.

In case of an article, please include authors in order of signature, year of publication, title of the article, name of the journal, volume, start page to end page.

If it's a book or chapter of a book, include its publisher and ISBN also.

If there are many authors, please indicate the total number of signatories and the position of the researcher (total number/ position of researcher) as for example 95/18.

**C.2. Participation in Research, Development and Innovation Projects**

Indicate the most important projects in which you have participated (maximum 5 to 7 projects), including a) its reference, b) title, c) funding body and call for proposals, d) name of the principal investigator and his/her institution affiliation, e) date of start and end of the project, f) amount of subsidy, and g) your type of participation, e.g.: researcher, principal investigator, European project coordinator, etc..

**C.3. Participation in Research, Development and Innovation Contracts**

Indicate the most important contracts in which you have participated (maximum 5 to 7 contracts), including a) title, b) company or entity, c) name of principal investigator and his/her institution affiliation, d) date of start and end of the contract, and e) amount of funding.

**C.4. Patents**

Indicate the most important patents and other intellectual property in which you have collaborated. Give a) the order of signing authors, b) reference, c) title, d) priority countries, e) date, f) holder entity and companies that are exploiting the patents.

**C.5, C.6, C.7… Other**

By sequential numbering (C.5, C.6, C.7 ...) please include any other achievements that you deem necessary, such as for example: direction of works, participation in assessment or advisory tasks, membership of international committees, management of scientific activity, editorial boards, **scientific awards**, etc.

**FINAL CONSIDERATIONS**

Please remember that all the submitted achievements must be presented concisely, including dates or periods for each performance.

The short CV aims to facilitate, organize and streamline the evaluation process. The use of the individual researcher identifier facilitates access to the published scientific papers and information on the impact of each of them.

**Remember that only CVs submitted either in this format or in CVN abridged version will be taken into consideration.**